viewPuma Biotechnology Inc

Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate

Puma won approval from the FDA for Nerlynx, which treats early-stage HER2-positive breast cancer, in July of 2017

cancer in headline
Revenue from Nerlynx accounted for the bulk of the $71.1 million in sales Puma reported in the fourth quarter

Shares of Puma Biotechnology (NASDAQ:PBYI) rocketed Friday after the biopharmaceutical company beat Wall Street’s fourth-quarter estimates thanks to sales of its flagship breast cancer drug Nerlynx (neratinib).

In its latest reporting period, the Los Angeles company’s net loss shrank to $12.2 million, or $0.32 per share, from a loss of $38.6 million, or $1.03 per share, in the year-ago quarter. Its sales amounted to $71.1 million, of which $61.1 million was revenue from Nerlynx and $10 million was license revenue.

Investors were impressed by the results, sending Puma shares up 28% to $35.60 in pre-market action before Friday’s opening bell.

READ: Puma Biotechnology’s 3Q earnings beat Street, but stock plummets as sale of cancer drug Nerlynx slows

Analysts had expected Puma to lose $0.69 and post revenue of $53.65 million.

Puma won approval from the US Food and Drug Administration for Nerlynx which treats early-stage HER2-positive breast cancer, in July of 2017. The drug has also been granted marketing authorization to treat early-stage breast cancer by the European Commission.

Contact Ellen [email protected]

Quick facts: Puma Biotechnology Inc

Price: 8.45 USD

Market: NASDAQ
Market Cap: $329.22 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



VolitionRx records first revenues from research kits and strengthens balance...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks Proactive London's Andrew Scott through the firm's third quarter update. He says excellent progress has been made on platform development - Nu.Q Capture, Nu.Q Vet and its colorectal cancer and lung cancer trials. Volition also...

29 minutes ago

2 min read